Seismic Therapeutic
- Industry
- Biotechnology
- Founded Year
- 2020
- Headquarters
- Watertown, Massachusetts, United States
- Employee Count
- 72
Key People
- Jo Viney, PhD - Founder, President and CEO
- Alan Crane - Founder, Chairman
- Timothy A. Springer, PhD - Founder
- Nathan Higginson-Scott, PhD - Chief Technology Officer and Senior VP Drug Creation
- Kevin Otipoby, PhD - Chief Research Officer
- John Sundy, MD, PhD - Chief Medical Officer and Head of R&D
- Melanie Manning - Chief People Officer
- Edward Freedman, JD - Chief Financial Officer
- Brendan St. Amant, JD - General Counsel
- Heather Vital - SVP of Development and Portfolio Strategy
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in biotechnology and immunology.
The leadership includes individuals like Jo Viney, PhD, with a strong track record in biotech, and Alan Crane, a seasoned entrepreneur, indicating a robust foundation for the company's strategic direction.
- Clinical Need
-
Aspect: Very Strong
Summary: Seismic Therapeutic addresses significant unmet needs in autoimmune disease treatment through innovative biologics.
Autoimmune diseases represent a substantial area of unmet medical need, and Seismic's approach using machine learning to develop biologics offers promising therapeutic advancements.
- Competition
-
Aspect: Somewhat crowded
Summary: The biotech sector focusing on immunology is competitive, with several companies pursuing similar goals.
While Seismic's integration of machine learning is innovative, the presence of other biotech firms in the immunology space necessitates strategic positioning to stand out.
- Technical Challenge
-
Aspect: Moderate
Summary: Integrating machine learning with biologics development presents moderate technical challenges.
Developing biologics using machine learning involves complex processes, but with the right expertise, these challenges can be effectively managed.
- Patent
-
Aspect: Applied
Summary: The company's patent portfolio is in the application stage, indicating ongoing efforts to secure intellectual property.
Securing patents for novel biologics and machine learning methodologies will protect the company's innovations and enhance its market position.
- Financing
-
Aspect: Well-funded
Summary: Seismic Therapeutic has raised significant funding, totaling $247 million, supporting its development programs.
The Series A and B financings, led by reputable investors, equip the company with the resources needed to advance its pipeline and platform development.
- Regulatory
-
Aspect: Running FIH
Summary: The company is progressing towards First-In-Human (FIH) trials for its lead programs.
As Seismic moves its lead candidates into clinical trials, adherence to regulatory requirements will be essential to ensure successful development and approval.
Opportunity Rollup
- Odds of Success
- 4.2
- Peak Market Share
- 6.2
- Segment CAGR
- 5.9%
- Market Segment
- Biologics for Autoimmune Diseases
- Market Sub Segment
- Machine Learning-Driven Drug Discovery
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.31 |
| 2 | 0.93 |
| 3 | 2.17 |
| 4 | 4.34 |
| 5 | 6.20 |
Key Takeaway
Seismic Therapeutic's integration of machine learning in biologics development positions it well in the growing autoimmune disease market, supported by strong leadership and substantial funding.